Clinical Trials Logo

Filter by:
NCT ID: NCT03357731 Completed - Heart Failure Clinical Trials

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.

NCT ID: NCT03355209 Active, not recruiting - Clinical trials for Lennox Gastaut Syndrome

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

Start date: November 27, 2017
Phase: Phase 3
Study type: Interventional

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

NCT ID: NCT03352557 Terminated - Alzheimer's Disease Clinical Trials

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

TANGO
Start date: May 3, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of the placebo-controlled period is to evaluate the safety and tolerability of BIIB092 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD. The secondary objectives of the placebo-controlled period are to evaluate the efficacy of multiple doses of BIIB092 in slowing cognitive and functional impairment in participants with MCI due to AD or with mild AD, and to evaluate the immunogenicity of BIIB092 after multiple doses in participants with MCI due to AD or with mild AD. The primary objective of the long-term extension period is to evaluate the long-term safety and tolerability of BIIB092 in participants with MCI due to AD or with mild AD.

NCT ID: NCT03351400 Active, not recruiting - Clinical trials for Chronic Heart Failure

Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration

JOKER
Start date: November 15, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of intracoronary infusion of autologous cardiac stem cells in patients with ischemic cardiomyopathy.

NCT ID: NCT03351244 Terminated - Schizophrenia Clinical Trials

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Start date: December 7, 2017
Phase: Phase 2
Study type: Interventional

The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.

NCT ID: NCT03351166 Completed - Anemia Clinical Trials

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

MIYABI HD-C
Start date: January 22, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Molidustat in dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs)

NCT ID: NCT03350503 Completed - Cataract Clinical Trials

AcrySof IQ Toric A-Code Post-Market Clinical Study

Start date: January 30, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to clinically confirm the rotational stability of a modified AcrySof IQ toric intraocular lens (IOL) in a Japanese population.

NCT ID: NCT03350386 Completed - Healthy Clinical Trials

Drug-drug Interaction Study of FYU-981 and Oxaprozin

Start date: November 2, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers.

NCT ID: NCT03350373 Completed - Healthy Clinical Trials

Clinical Pharmacology of FYU-981 (Final Formulation)

Start date: November 6, 2017
Phase: Phase 1
Study type: Interventional

This is a randomized, open-label, 2-period crossover study. The purpose of this study is to assess the pharmacokinetics and safety after single oral administration of final formulation of FYU-981 to healthy male adults in fasted and fed conditions. Participants are randomized to fasted (n=6) or fed conditions (n=6) in each step. The effect of food to pharmacokinetics of FYU-981 is also investigated.

NCT ID: NCT03350347 Completed - Anemia Clinical Trials

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects

MIYABI ND-M
Start date: December 13, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects previously treated with Erythropoiesis-Stimulating Agents (ESAs)